Lori Berk

957 total citations
20 papers, 785 citations indexed

About

Lori Berk is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Lori Berk has authored 20 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 8 papers in Hematology and 7 papers in Genetics. Recurrent topics in Lori Berk's work include PI3K/AKT/mTOR signaling in cancer (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Virus-based gene therapy research (3 papers). Lori Berk is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Virus-based gene therapy research (3 papers). Lori Berk collaborates with scholars based in United States, Switzerland and Italy. Lori Berk's co-authors include Victor M. Rivera, Tim Clackson, Teresa Druck, Kay Huebner, Frank G. Haluska, John W. Loewy, Hansjüerg Alder, Koshi Mimori, Carlo M. Croce and Anthony W. Tolcher and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Lori Berk

20 papers receiving 770 citations

Peers

Countries citing papers authored by Lori Berk

Since Specialization

Citations

This map shows the geographic impact of Lori Berk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori Berk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori Berk more than expected).

Fields of papers citing papers by Lori Berk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori Berk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori Berk. The network helps show where Lori Berk may publish in the future.

Co-authorship network of co-authors of Lori Berk

This figure shows the co-authorship network connecting the top 25 collaborators of Lori Berk. A scholar is included among the top collaborators of Lori Berk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori Berk. Lori Berk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma 2012 ·Annals of Oncology ·Monica Mita, Elizabeth Poplin, Carolyn D. Britten, William D. Tap, Eric H. Rubin, B. B. Scott, Lori Berk, Victor M. Rivera, John W. Loewy, P. Dodion, Frank G. Haluska, John Sarantopoulos, Alain C. Mita, Anthony W. Tolcher	30
2	Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial 2012 ·Cancer Chemotherapy and Pharmacology ·Lori Berk, Monica Mita, (unknown), Camille L. Bedrosian, Anthony W. Tolcher, Tim Clackson, Victor M. Rivera	14
3	Dimerizer-Mediated Regulation of Gene Expression 2012 ·Cold Spring Harbor Protocols ·Victor M. Rivera, Lori Berk, Tim Clackson	5
4	Dimerizer-Mediated Regulation of Gene Expression In Vivo 2012 ·Cold Spring Harbor Protocols ·Victor M. Rivera, Lori Berk, Tim Clackson	14
5	Dimerizer-Mediated Regulation of Gene Expression In Vitro 2012 ·Cold Spring Harbor Protocols ·Victor M. Rivera, Lori Berk, Tim Clackson	6
6	Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens 2011 ·Molecular Cancer Therapeutics ·Victor M. Rivera, Rachel M. Squillace, David F. Miller, Lori Berk, Scott Wardwell, Yaoyu Ning, Roy M. Pollock, Narayana I. Narasimhan, John D. Iuliucci, Frank Wang, Tim Clackson	87
7	Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial 2011 ·Cancer Chemotherapy and Pharmacology ·David A. Reardon, Patrick Y. Wen, W. K. Alfred Yung, Lori Berk, Narayana I. Narasimhan, Christopher Turner, Timothy Piers Clackson, Victor M. Rivera, Michael A. Vogelbaum	15
8	Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas 2011 ·Journal of Clinical Oncology ·Sant P. Chawla, Arthur P. Staddon, Laurence H. Baker, Scott M. Schuetze, Anthony W. Tolcher, Gina Z. D’Amato, Jean‐Yves Blay, Monica Mita, Kamalesh K. Sankhala, Lori Berk, Victor M. Rivera, Tim Clackson, John W. Loewy, Frank G. Haluska, George D. Demetri	195
9	Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine 2010 ·Journal of Clinical Oncology ·Antonella Perotti, Alberta Locatelli, Cristiana Sessa, Dagmar Hess, Lucia Viganò, Giuseppe Capri, Michela Maur, Thomas Cerny, Sara Cresta, Federico Rojo, Joan Albanell, Silvia Marsoni, (unknown), Lori Berk, Victor M. Rivera, Frank G. Haluska, Luca Gianni	36
10	Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel 2009 ·Annals of Oncology ·Cristiana Sessa, Diégo Tosi, Lucia Viganò, Joan Albanell, Dagmar Hess, (unknown), Sara Cresta, Alberta Locatelli, (unknown), Federico Rojo, N. Coceani, Victor M. Rivera, Lori Berk, Frank G. Haluska, Luca Gianni	47
11	A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies 2009 ·Clinical Cancer Research ·Christine Hartford, Apurva A. Desai, Linda Janisch, Theodore Karrison, Victor M. Rivera, Lori Berk, John W. Loewy, Hedy L. Kindler, Walter M. Stadler, Heather Knowles, Camille L. Bedrosian, Mark J. Ratain	71
12	A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations. 2009 ·Blood ·Jörge E. Cortes, Moshe Talpaz, Michael W. Deininger, Neil P. Shah, Ian W. Flinn, Michael J. Mauro, Thomas O’Hare, (unknown), Simin Hu, Lori Berk, Narayana I. Narasimhan, Victor M. Rivera, Tim Clackson, Frank G. Haluska, Hagop M. Kantarjian	26
13	Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML) 2008 ·Blood ·Victor M. Rivera, Qihong Xu, Lori Berk, Jeffrey Keats, Scott Wardwell, Frank Wang, William C. Shakespeare, Tim Clackson	7
14	Detection and frequency estimation of rare variants in pools of genomic DNA from large populations using mutational spectrometry 2005 ·Mutation research. Fundamental and molecular mechanisms of mutagenesis ·Xiaocheng Li-Sucholeiki, Aoy Tomita‐Mitchell, Kevin Arnold, Brian Glassner, Terri G. Thompson, (unknown), Lori Berk, (unknown), (unknown), (unknown), (unknown), Donald M. Cannon, (unknown), (unknown), Chiranjit Deka, Barry L. Karger, Kathleen M. Gillespie, Per Olaf Ekstrøm, John A. Todd, William G. Thilly	14
15	Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats 2005 ·Molecular Therapy ·Laura Sanftner, Victor M. Rivera, Brian M. Suzuki, Feng Lan, Lori Berk, Shangzhen Zhou, John Forsayeth, Tim Clackson, Janet Cunningham	21
16	390 A phase I trial of weekly AP23573, a novel mTOR inhibitor, in patients with advanced or refractory malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis 2004 ·European Journal of Cancer Supplements ·Apurva A. Desai, Linda Janisch, Lori Berk, Heather Knowles, Victor M. Rivera, Hedy L. Kindler, Walter M. Stadler, Camille L. Bedrosian, Mark J. Ratain	1
17	411 Pharmacodynamic evaluation of the mTOR inhibitor AP23573 in phase 1 clinical trials 2004 ·European Journal of Cancer Supplements ·Victor M. Rivera, Lori Berk, Monica Mita, (unknown), Eric K. Rowinsky, (unknown), Mark J. Ratain, Timothy Piers Clackson, Camille L. Bedrosian	3
18	Sequence conservation at human and mouse orthologous common fragile regions, FRA3B / FHIT and Fra14A2 / Fhit 2001 ·Proceedings of the National Academy of Sciences ·Takeshi Shiraishi, Teresa Druck, Koshi Mimori, (unknown), Lori Berk, Hansjüerg Alder, Webb Miller, Kay Huebner, Carlo M. Croce	58
19	Cancer-specific chromosome alterations in the constitutive fragile region FRA3 B 1999 ·Proceedings of the National Academy of Sciences ·Koshi Mimori, Teresa Druck, Hiroshi Inoue, Hansjüerg Alder, Lori Berk, Masaki Mori, Kay Huebner, Carlo M. Croce	106
20	FHITness and cancer. 1998 ·PubMed ·Teresa Druck, Lori Berk, Kay Huebner	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact